Sinopharm Group Co (STU:X2S) Common Stock: €378 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:X2S Sinopharm Group Co Ltd STU:X2S
68 GF Score
Price €1.93
GF Value €2.30
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Common Stock?

Sinopharm Group Co STU:X2S -1.61% 68 Common Stock is €378 Mil as of Dec. 2025. GuruFocus rates STU:X2S with a GF Score™ of 68/100 and a GF Value™ of €2.30 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sinopharm Group Co's quarterly common stock declined from Dec. 2024 (€409 Mil) to Jun. 2025 (€377 Mil) but then increased from Jun. 2025 (€377 Mil) to Dec. 2025 (€378 Mil).

Sinopharm Group Co's annual common stock increased from Dec. 2023 (€401 Mil) to Dec. 2024 (€409 Mil) but then declined from Dec. 2024 (€409 Mil) to Dec. 2025 (€378 Mil).

Sinopharm Group Co Common Stock Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Common Stock Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 433.61 422.55 400.78 409.33 378.39

Sinopharm Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 400.78 399.62 409.33 376.81 378.39
STU:X2S
68GF Score
Sinopharm Group Co Ltd STU:X2S
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €378 Mil mean?
Sinopharm Group Co (STU:X2S) has a Common Stock of €378 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Common Stock too high?
Sinopharm Group Co's current Common Stock is €378 Mil. Overall, Sinopharm Group Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Common Stock compare to MCK and CAH?
Sinopharm Group Co's Common Stock of €378 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Distribution company?
A good Common Stock depends on the Medical Distribution industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Common Stock is €378 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (STU:X2S) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.30, compared to a current price of €1.93 — trading 16.2% below its estimated fair value. The current Common Stock is €378 Mil. Sinopharm Group Co's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Sinopharm Group Co (STU:X2S), the current Common Stock is €378 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (STU:X2S) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of €1.93 is trading 16.2% below its estimated GF Value™ of €2.30. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for STU:X2S:

  • Common Stock: €378 Mil
  • GF Value™: €2.30 vs. price of €1.93 (16.2% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the STU:X2S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
68GF Score

Get the complete analysis for STU:X2S

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€2.30
GF Value